PALO ALTO, Calif.--(BUSINESS WIRE)--CerebraAI, an AI-driven neuroradiology software company focused on acute ischemic stroke detection, is honored to welcome AI industry leader Dr. Jia Li and accomplished product creator, operator, and investor Shea Tate-Di Donna to its Advisory Board. Guiding CerebraAI’s R&D and fundraising pathways, Dr. Li and Shea Tate-Di Donna join an esteemed group of advisors in their respective fields to support CerebraAI in the process of developing its brain imaging analysis map. With a novel approach of creating personalized AI-generated images of the patient’s pseudo-healthy brain to enhance non-contrast CT (NCCT) scans, the deep-learning AI model is being developed for physicians to rapidly diagnose acute ischemic stroke.
Dr. Jia Li’s pioneering accomplishments in AI span more than two decades of industry-leading recognition. In addition to her distinguished leadership as an IEEE Fellow, Founding Head of R&D and Co-founder of Google Cloud AI, and previous roles including Adjunct Professor and inaugural course instructor for Generative AI in Medicine at Stanford University, she is Co-founder, Chief AI Officer, and President of LiveX AI, empowering businesses with a trusted AI Agent for unmatched customer engagement across all platforms. With a dedicated passion for making a positive impact in healthcare through generative AI, Jia also co-founded and is Board Chair of HealthUnity, an open consortium of data scientists, AI experts, and healthcare visionaries building metrics and benchmarks to help guide the industry.
“I first met CerebraAI as the Digital Health winner of our HealthUnity Generative AI in Healthcare Startup Challenge at Stanford in 2023,” stated Dr. Jia Li, Co-founder, Chief AI Officer, and President of LiveX AI and Board Chair, Co-founder of HealthUnity. “CerebraAI impressed our highly respected industry judges then and continues to deliver on leading-edge technologies being developed to help close the severe emergency care diagnostics gap through its novel generative AI medical imaging approach. Currently, 94% of emergency departments in the U.S. are capable of drug intervention but only 20% of stroke victims receive treatment. AI can change this.”
Known for fostering high-growth companies and her extensive early stage venture capital experience, Shea Tate-Di Donna has pioneered seven VC firms and is an accomplished entrepreneur, fundraising strategist, and AI enthusiast. She was part of the founding team at True Ventures and has held integral roles at Pivotal Ventures, First Republic Bank, 1517 Fund, Mythos Ventures, and multiple startups. Author of The Venture Fund Blueprint: How to Access Capital, Achieve Launch, and Actualize Growth, she has educated thousands of entrepreneurs and emerging fund managers driving growth and innovation in the tech industry. With a rich blend of industry insights and a robust deal network, Shea’s strategic fundraising role on CerebraAI’s Advisory Board is set to transform the company’s strategic vision into actionable results for continued growth and lasting impact.
“I am committed to driving progressive change in the AI startup sector and thrilled to be supporting the continued advancement of CerebraAI’s transformative technology,” stated Shea Tate-Di Donna, early stage AI venture expert and CerebraAI advisor. “With early stage ventures, it is all about the people; I believe in Dos, his team, and their commitment to utilizing AI for early stroke detection and treatment. Their innovative approach has the potential to revolutionize stroke care and save countless lives. This is AI at its best, making a positive impact with a focus on improved patient outcomes, and I am excited to support its introduction to the investment community.”
“We are incredibly honored to welcome Shea Tate-Di Donna and Dr. Jia Li as our newest members of the CerebraAI Advisory Board,” stated Doszhan Zhussupov, CerebraAI Founder and CEO. “Jia is quite the celebrity as an AI pioneer and highly respected industry leader building and advising companies with award-winning platforms and advancing trustworthy AI in healthcare. Shea’s extensive high-tech venture experience and renowned work in transforming companies are a testament to what she is bringing to CerebraAI through her strategic excellence and thoughtful execution of each round. We are extremely grateful to have their expertise and support.”
In addition to expert advisors supporting CerebraAI, the medical imaging AI startup has received a warm welcome into multiple top startup accelerators since relocating its headquarters from Kazakhstan to the U.S. in February of 2024, including a recent invitation to participate in MassChallenge’s 2024 U.S. Early Stage Cohort after rigorous rounds of judging and being selected as part of a standout group from more than 1,300 startup applications. CerebraAI is also the first startup from Central Asia to be accepted into the highly-vetted community of Stanford alumni and professor founders at StartX and is honored to be a part of the Microsoft for Startups Founders Hub, NVIDIA Inception Program, MedTech Innovators, UC Berkeley’s Health Engine Accelerator, and the vibrant community of Central Eurasia tech startups at the Silkroad Innovation Hub in Silicon Valley.
About CerebraAI
Founded in 2018, CerebraAI is developing medical imaging software for acute ischemic stroke detection through the power of generative AI. Pioneering the development of a personalized AI-generated digital twin of the patient’s pseudo-healthy brain based on non-contrast CT (NCCT) scans, CerebraAI aims to leverage its brain imaging algorithm to detect tissue abnormalities through a detailed analysis map for accelerated diagnosis, triage, and treatment of acute ischemic stroke victims. The software is being designed for use on a mobile app or web-based platform. Currently in use in 47 hospitals in Kazakhstan, two Uzbekistan hospitals, and four hospitals in Saudi Arabia in pilot mode, with more than 150,000 patients analyzed, CerebraAI’s medical imaging software is not yet approved in the U.S. The company recently relocated its headquarters from Kazakhstan to Silicon Valley for this continued U.S. product development, in addition to expansion plans in multiple markets globally.
In 2022, StartUs Insights ranked CerebraAI’s deep learning model among the top five global projects for diagnosing brain diseases and the company has received global recognition, including Intel Software’s AI Startup Olympics grand prize, Johnson & Johnson Impact Ventures’ HealthTech Startups in APAC top award, EY’s Best Innovative Startup honor, Medtronic’s Top 10 Most Innovative Medical AI Startups in APAC in 2022, HealthUnity’s Generative AI Startup Challenge Digital Health winner, the Digital Almaty Best MedTech Award, Global Startup Awards’ Best VerTech Startup, the Global Health Exhibition Innov8 Competition winner, the TechCrunch Startup Battlefield 200 2023, and the LEAP 2024 Artificial Intelligence Award. For more information, please visit www.CerebraAI.ai and follow us on LinkedIn.
